Axogen, Inc. Files Definitive Proxy Statement (DEF 14A)

Ticker: AXGN · Form: DEF 14A · Filed: Apr 24, 2024 · CIK: 805928

Axogen, Inc. DEF 14A Filing Summary
FieldDetail
CompanyAxogen, Inc. (AXGN)
Form TypeDEF 14A
Filed DateApr 24, 2024
Risk Levellow
Pages16
Reading Time19 min
Key Dollar Amounts$20,000
Sentimentneutral

Sentiment: neutral

Topics: DEF 14A, Proxy Statement, Axogen, SEC Filing, Corporate Governance

TL;DR

<b>Axogen, Inc. has filed its Definitive Proxy Statement (DEF 14A) for the period ending June 5, 2024.</b>

AI Summary

Axogen, Inc. (AXGN) filed a Proxy Statement (DEF 14A) with the SEC on April 24, 2024. Axogen, Inc. filed a DEF 14A form on April 24, 2024, for the period ending June 5, 2024. The filing includes data for fiscal years 2020 through 2023. The company's principal executive offices are located in Alachua, Florida. Axogen, Inc. was formerly known as AxoGen, Inc. and LECTEC CORP /MN/. The filing pertains to the 1934 Securities Exchange Act.

Why It Matters

For investors and stakeholders tracking Axogen, Inc., this filing contains several important signals. This filing is a standard regulatory requirement for public companies, providing shareholders with information regarding annual meetings, executive compensation, and voting matters. The DEF 14A filing allows shareholders to make informed decisions about company governance and proposals presented at the annual meeting.

Risk Assessment

Risk Level: low — Axogen, Inc. shows low risk based on this filing. The filing is a routine DEF 14A, indicating no immediate material events or significant changes are being disclosed beyond standard corporate governance information.

Analyst Insight

Review the proxy statement for details on executive compensation, board nominations, and any shareholder proposals to understand management's strategy and potential impacts on shareholder value.

Key Numbers

  • 2024-06-05 — Period of Report (DEF 14A)
  • 2024-04-24 — Filed as of Date (DEF 14A)
  • 2023-12-31 — Fiscal Year End (Company Data)
  • 1934 — SEC Act (Filing Values)

Key Players & Entities

  • Axogen, Inc. (company) — Filer
  • AxoGen, Inc. (company) — Former company name
  • LECTEC CORP /MN/ (company) — Former company name
  • Alachua, Florida (location) — Business address

FAQ

When did Axogen, Inc. file this DEF 14A?

Axogen, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 24, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Axogen, Inc. (AXGN).

Where can I read the original DEF 14A filing from Axogen, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Axogen, Inc..

What are the key takeaways from Axogen, Inc.'s DEF 14A?

Axogen, Inc. filed this DEF 14A on April 24, 2024. Key takeaways: Axogen, Inc. filed a DEF 14A form on April 24, 2024, for the period ending June 5, 2024.. The filing includes data for fiscal years 2020 through 2023.. The company's principal executive offices are located in Alachua, Florida..

Is Axogen, Inc. a risky investment based on this filing?

Based on this DEF 14A, Axogen, Inc. presents a relatively low-risk profile. The filing is a routine DEF 14A, indicating no immediate material events or significant changes are being disclosed beyond standard corporate governance information.

What should investors do after reading Axogen, Inc.'s DEF 14A?

Review the proxy statement for details on executive compensation, board nominations, and any shareholder proposals to understand management's strategy and potential impacts on shareholder value. The overall sentiment from this filing is neutral.

How does Axogen, Inc. compare to its industry peers?

Axogen, Inc. operates in the electromedical and electrotherapeutic apparatus industry.

Are there regulatory concerns for Axogen, Inc.?

The filing is made under the Securities Exchange Act of 1934, requiring public companies to disclose information relevant to shareholder voting and corporate governance.

Industry Context

Axogen, Inc. operates in the electromedical and electrotherapeutic apparatus industry.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, requiring public companies to disclose information relevant to shareholder voting and corporate governance.

What Investors Should Do

  1. Analyze executive compensation details to assess alignment with company performance.
  2. Review board member nominations and qualifications.
  3. Examine any shareholder proposals and the company's recommendation.

Key Dates

  • 2024-04-24: Filing Date — Definitive Proxy Statement (DEF 14A) filed.
  • 2024-06-05: Period of Report — The reporting period for the DEF 14A.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a routine disclosure. No direct comparison to a prior filing's specific financial or operational metrics is possible from this document alone.

Filing Stats: 4,712 words · 19 min read · ~16 pages · Grade level 12.8 · Accepted 2024-04-24 07:32:45

Key Financial Figures

  • $20,000 — tion of proxies for an estimated fee of $20,000 plus expenses. The proxy solicitor may

Filing Documents

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 18 Equity Compensation Plan Information 23

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 24 COMPENSATION DISCUSSION AND ANALYSIS 24 Executive Summary 24 Say on Pay Vote and Investor Feedback 29 Pay Program Overview 30 Compensation Governance 30

Executive Compensation Philosophy and Objectives

Executive Compensation Philosophy and Objectives 32 Compensation-Setting Process 32 Use of Competitive Data 33 Consideration of Compensation Risk 34

Executive Compensation Program Components

Executive Compensation Program Components 35 2023 Annual Cash Incentives 36 Equity Compensation 38 Additional Compensation Practices and Policies 41 COMPENSATION COMMITTEE REPORT 35 Summary Compensation Table 36 1 Table of Contents CEO Pay Ratio Disclosure 57 Grants of Plan-Based Awards 47 Outstanding Equity Awards at 2023 Fiscal Year-End 49 Option Exercises and Stock Vested 50 Potential Payments Upon Termination or Change in Control 50 Employment Agreements 41 DIRECTOR COMPENSATION 64 REPORT OF THE AUDIT COMMITTEE 65 PROPOSAL 2 – RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 66 Independent Registered Public Accounting Firm 66 Information Regarding Independent Registered Public Accounting Firm 66 PROPOSAL 3 – NON-BINDING ADVISORY VOTE ON NAMED EXECUTIVE OFFICER COMPENSATION 67 PROPOSAL 4 - APPROVAL OF THE AXOGEN, INC. THIRD AMENDED AND RESTATED 2019 LONG-TERM INCENTIVE TO INCREASE THE NUMBER OF SHARES AUTHORIZED FOR ISSUANCE THEREUNDER FROM 8,000,000 TO 10,500,000 68 PROPOSALS FOR OUR 2025 ANNUAL MEETING 75 ANNUAL REPORT ON FORM 10-K 76 "HOUSEHOLDING" OF PROXY MATERIALS 76 OTHER MATTERS 77 APPENDIX A A 2 Axogen, Inc. 13631 Progress Blvd. Suite 400 Alachua, FL 32615 PROXY STATEMENT 2024 Annual Meeting of Shareholders TO BE HELD ON JUNE 5, 2024 The board of directors (the "Board of Directors") of Axogen, Inc. (the "Company", "Axogen", "we" or "our") is soliciting proxies for use at our 2024 Annual Meeting of Shareholders (the "Meeting") which will be conducted via live audio webcast and accessible at www.virtualshareholdermeeting.com/axogen2024 on June 5, 2024, at 8:00 a.m. Eastern time and at any adjournment or postponement thereof. This Proxy Statement and the enclosed proxy card are first being mailed to shareholders on or about April 24, 2024. Our Board of Directors has set Friday, April 19, 2024, as the record date for the Meeting. Each shareholder

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.